SOURCE: SomaLogic

SomaLogic

November 18, 2014 11:00 ET

SomaLogic Announces Deployment of SOMAscan™ Proteomics Assay at University of Colorado Denver

Anschutz Medical Campus Researchers to Receive Access to SOMAscan Assay Through Genomics and Microarray Core Facility

DENVER, CO and BOULDER, CO--(Marketwired - November 18, 2014) - SomaLogic, Inc., announced today that the SOMAscan™ assay, a breakthrough proteomics platform, will be deployed at the University of Colorado Denver (UCD), Anschutz Medical Campus. The assay will be performed for UCD's basic and clinical researchers under the direction of Mark Geraci, MD, Head of the Division of Pulmonary Sciences and Critical Care Medicine, and Bifeng Gao, PhD, Director and Manager of UCD's Genomics and Microarray Core. It is expected that the SOMAscan assay will be installed and fully functional at UCD by early 2015.

"We are excited to be able to offer our research colleagues a way to perform critical proteomics studies to complement the genomics assays we currently provide," said Dr. Geraci. "I believe that SomaLogic's SOMAscan assay will accelerate not only our understanding of the many different diseases being studied here, but will also point to potential new therapeutic approaches."

Compared to other current proteomic technologies, SomaLogic's offerings give researchers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

"We are delighted to partner with the University of Colorado to make our technology more accessible to its great research scientists," said Byron Hewett, Chief Executive Officer of SomaLogic. "We have had several highly successful collaborations with individual CU researchers in the past, and this new joint effort will lead to even more important discoveries with our Colorado neighbors and colleagues."

The University of Colorado Denver joins the University of Pennsylvania, Massachusetts General Hospital, and the National Institutes of Health as a SOMAscan assay site. SomaLogic is continuing to expand access to its SOMAscan platform through its placement in leading academic research centers, and anticipates announcing additional SOMAscan assay sites over the next several months.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

Contact Information